Nuvalent (NUVL) Return on Capital Employed (2021 - 2026)
Nuvalent (NUVL) posted Return on Capital Employed of 34.0% for Q1 2026, up 9.31% on a QoQ basis from 37.49% in Q4 2025, and down 324.0% year-over-year from 15.18% in Q1 2025.
Nuvalent (NUVL) Return on Capital Employed (2021 - 2026) Analysis & Trends
Nuvalent's Return on Capital Employed history runs 6 years deep, the most recent figure standing at 34.0% for Q1 2026.
- Quarterly Return on Capital Employed fell 324.0% year-over-year to 34.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 34.0% (down 324.0% YoY) and the FY2025 annual result came in at 34.93%, down 318.0% from the prior year.
- Return on Capital Employed was 34.0% for Q1 2026 at Nuvalent, up from 37.49% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 20.68% in Q1 2022 and bottomed at 43.25% in Q3 2025.
- A 5-year average of 29.42% and a median of 27.33% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed jumped 543 bps — and 2025, when it slumped 1595 bps.
- Nuvalent's Return on Capital Employed stood at 24.85% in 2022, then slipped by 10 bps to 27.33% in 2023, then rose by 8 bps to 25.23% in 2024, then tumbled by 49 bps to 37.49% in 2025, then advanced by 9 bps to 34.0% in 2026.
- Business Quant data shows NUVL's Return on Capital Employed at 34.0% in Q1 2026, 37.49% in Q4 2025, and 43.25% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - | -34.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.00% |
| Dec 31, 2025 | -37.49% |
| Sep 30, 2025 | -43.25% |
| Jun 30, 2025 | -36.27% |
| Mar 31, 2025 | -30.76% |
| Dec 31, 2024 | -25.23% |
| Sep 30, 2024 | -27.30% |
| Jun 30, 2024 | -31.05% |
| Mar 31, 2024 | -25.02% |
| Dec 31, 2023 | -27.33% |
| Sep 30, 2023 | -32.73% |
| Jun 30, 2023 | -26.46% |
| Mar 31, 2023 | -21.69% |
| Dec 31, 2022 | -24.85% |
| Sep 30, 2022 | -30.49% |
| Jun 30, 2022 | -25.47% |
| Mar 31, 2022 | -20.68% |
| Dec 31, 2021 | -15.68% |
| Sep 30, 2021 | -15.37% |